Today: 20 May 2026
CrowdStrike stock (CRWD) slips after hours as CEO pay filing and Wedbush’s $600 target hit year-end tape
1 January 2026
1 min read

CrowdStrike stock (CRWD) slips after hours as CEO pay filing and Wedbush’s $600 target hit year-end tape

NEW YORK, December 31, 2025, 19:42 ET — After-hours

  • CrowdStrike shares were down about 1.5% after the bell at $468.76.
  • A newly filed 8-K detailed a performance-based equity award for CEO George Kurtz tied to S&P 500-relative returns through 2028.
  • Wedbush’s Dan Ives reiterated a $600 price target and flagged CrowdStrike as a key AI-linked cyber play for 2026.

CrowdStrike Holdings shares slipped about 1.5% in after-hours trading on Wednesday, leaving the cybersecurity firm at $468.76.

The move capped a soft finish for U.S. equities as investors closed the books on 2025, a year fueled by euphoria around AI-focused stocks, Reuters reported.

CrowdStrike drew fresh attention this week after it filed an 8-K describing a new, long-term performance stock unit award for CEO George Kurtz, according to the Securities and Exchange Commission filing.

Performance stock units are equity awards that pay out only if targets are met. CrowdStrike said the award’s performance period runs from December 22, 2025 through December 22, 2028.

The payout is tied to total shareholder return (TSR) — stock price gains plus dividends reinvested — relative to the companies in the S&P 500, the filing and award agreement show.

At target, Kurtz received 300,000 performance units, with a sliding scale from zero to a maximum 600,000 shares if CrowdStrike’s TSR ranks at the 90th percentile or higher versus S&P 500 peers, the agreement shows.

CrowdStrike said the award is intended to retain Kurtz and align incentives with shareholders as the company pursues an ambition to reach $20 billion in annual recurring revenue (ARR), a subscription metric that tracks contracted revenue expected each year.

Bullish analyst commentary also stayed in the mix. Wedbush Securities analyst Dan Ives reiterated a $600 price target and wrote: “CrowdStrike remains one of our favorite tech names,” according to a Business Insider summary of his note. Business Insider

In the regular session, CrowdStrike traded between $468.48 and $476.84, with about 1.66 million shares changing hands, market data showed.

Cybersecurity peers were also lower late in the day. Palo Alto Networks fell about 1.4%, Zscaler was down about 1.1% and Fortinet slipped about 1.1%.

A separate Form 4 filing showed Chief Accounting Officer Anurag Saha sold 836 shares on December 24 at $476.83 under a Rule 10b5-1 plan — a pre-arranged trading plan that allows insiders to sell shares on a set schedule.

Broader risk appetite remained cautious into the close. The S&P 500 fell 0.74% and the Nasdaq lost 0.76% in the year’s final session, Reuters reported, adding that U.S. markets are closed on Thursday for New Year’s Day.

What investors watch next is whether CrowdStrike holds the mid-$460s area when liquidity returns on Friday, and how the stock tracks versus the broader market as Kurtz’s new award ties future payouts to S&P 500-relative performance. The company’s fiscal year ends January 31, and earnings calendars are already pointing to early March for the next results update, though CrowdStrike has not announced a date.

Stock Market Today

  • Euronext Q1 2026 Sees Record Trading Volumes and 15.3% Revenue Growth
    May 20, 2026, 5:43 AM EDT. Euronext reported a record Q1 2026 with cash equity trading and clearing revenue up 30.8% to €123 million, driven by high market volatility and the full contribution from Euronext Athens. Total underlying revenue rose 15.3% to €528.5 million, marking the exchange's eighth consecutive quarter of double-digit growth. Average daily cash equity transaction value in April reached €16.4 billion, with a 64.1% market share. Commodities trading revenue climbed 13.9%, while FX revenue grew 5.8%. ETF trading surged 84% since September 2025, boosted by the launch of mini ETF options. Adjusted EBITDA rose 16.7% to €343.2 million, with net income up 17.7%. Euronext declared a €3.18 dividend per share, reflecting a 50% payout, payable in May.

Latest articles

Co-Diagnostics Stock Surges — Then $3 Million Financing Puts The Rally To The Test

Co-Diagnostics Stock Surges — Then $3 Million Financing Puts The Rally To The Test

20 May 2026
New York, May 20, 2026, 05:08 EDT Co-Diagnostics shares face an early test on Wednesday after the diagnostic-test developer announced a $3 million private placement hours after its stock closed up 43.8% at $1.97 on Tuesday. Extended-hours trading showed the shares down 13.3% at $1.71 before the regular Nasdaq session. The timing matters. Co-Diagnostics had rallied after saying it had completed a strategy to develop an assay, or diagnostic test, for the Bundibugyo virus behind a fast-moving Ebola outbreak in Democratic Republic of Congo and Uganda. The late financing then shifted attention to dilution and cash needs. The company said
Micron Stock Just Dodged the Nasdaq Selloff. A Samsung Strike Could Be Its Next Jolt

Micron Stock Just Dodged the Nasdaq Selloff. A Samsung Strike Could Be Its Next Jolt

20 May 2026
Micron Technology shares rose 2.5% Tuesday to $698.74, lifting its market value near $798 billion as the Nasdaq fell. Analysts cited tight memory supply and strong DRAM and NAND pricing. A planned strike by 48,000 Samsung workers Thursday could disrupt global memory supply, potentially raising prices. Micron recently sampled 256GB DDR5 server modules to partners.
Wall Street Puts $150 Target on Intel in AI Push

Wall Street Puts $150 Target on Intel in AI Push

20 May 2026
Intel shares rose 2.43% to $110.80 on Tuesday, ending a five-day losing streak. The stock rebounded as analysts raised price targets, citing demand for AI server CPUs. Intel traded between $102.40 and $113.07 during the session. The Nasdaq Composite fell 0.84%, with Nvidia and AMD also down.
AI stocks today: Nvidia, AMD tick higher as year-end trade turns cautious
Previous Story

AI stocks today: Nvidia, AMD tick higher as year-end trade turns cautious

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD
Next Story

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Go toTop